GNH USA

Europe — EMA

Lapatinib Teva

GNH USA supplies Lapatinib Teva (Lapatinib), a tyrosine kinase inhibitor for HER2‑positive metastatic breast cancer and gastric cancer.

Lapatinib

Request sourcing

1
Pack/s

What is Lapatinib?

Lapatinib, the active ingredient in Lapatinib Teva, is a tyrosine kinase inhibitor presented as an unknown strength/oral dosage form for oral use. It targets HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric or gastro‑oesophageal junction adenocarcinoma. GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

What is Lapatinib used for?

Lapatinib acts on HER2‑driven tumor pathways and is used in advanced HER2‑positive cancers.

- HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with other HER2‑targeted agents. - HER2‑positive metastatic gastric cancer: contributes to disease control in combination regimens. - HER2‑positive gastro‑oesophageal junction adenocarcinoma: used as part of multi‑drug therapy to delay tumor progression.

What are the side effects of Lapatinib?

Lapatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools. - Rash: skin irritation, often on the trunk. - Nausea: feeling of sickness. - Fatigue: reduced energy levels. - Stomatitis: inflammation of the mouth lining. - Elevated liver enzymes: increased ALT/AST.

Serious or Rare Side Effects: - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: clinically significant liver injury. - Interstitial lung disease: breathing difficulties and cough. - Severe diarrhea leading to dehydration. - Thromboembolic events: blood clot formation.

What precautions apply to Lapatinib?

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor key parameters.

- Cardiac assessment: baseline and periodic echocardiograms for patients with cardiac history. - Liver function: monitor ALT, AST, and bilirubin before and during treatment. - Dermatologic monitoring: watch for severe rash or skin reactions. - Gastrointestinal vigilance: assess for persistent diarrhea or dehydration. - Drug interactions: review concomitant medications that affect CYP3A4. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

What does Lapatinib interact with?

Lapatinib’s metabolism involves CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may lower absorption; separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: potential increase in serum levels; observe for toxicity. - Simvastatin: increased risk of myopathy; consider dose adjustment. - Proton pump inhibitors: may modestly affect bioavailability.

Frequently asked questions

What conditions is Lapatinib Teva used to treat?+
Lapatinib Teva is indicated for HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric or gastro‑oesophageal junction adenocarcinoma. In these settings it is used as part of combination regimens to improve disease control and delay progression.
How does lapatinib work at the molecular level?+
Lapatinib blocks the intracellular tyrosine kinase activity of EGFR (ErbB1) and HER2 (ErbB2). This inhibition stops downstream signaling through pathways such as MAPK and PI3K/AKT, which are essential for tumor cell growth, survival, and angiogenesis, thereby slowing cancer progression.
What is the usual dose of Lapatinib Teva?+
The specific dose of Lapatinib Teva is determined by the prescribing oncologist based on the patient’s clinical condition, treatment regimen, and tolerability. Dosing recommendations are provided in the product’s prescribing information and should be followed exactly as directed by a qualified healthcare professional.
Is Lapatinib Teva safe to use during pregnancy or breastfeeding?+
Safety data for Lapatinib Teva in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk to the fetus. Breastfeeding is not recommended while on therapy because the drug may be excreted in milk and could affect the infant.
How do I order Lapatinib Teva from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Lapatinib compare with other HER2‑targeted therapies?+
Lapatinib is a small‑molecule tyrosine kinase inhibitor that targets both EGFR and HER2 intracellularly, whereas monoclonal antibodies such as trastuzumab bind extracellular HER2 domains. Lapatinib can be combined with trastuzumab or chemotherapy, offering a complementary mechanism of action and an oral administration route.
What are the recommended storage conditions for Lapatinib Teva?+
Lapatinib Teva should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.
How is Lapatinib Teva administered to patients?+
Lapatinib Teva is taken orally, usually as a tablet, with a glass of water. It is commonly administered once daily, and patients are advised to follow the specific timing and food‑related instructions provided by their healthcare provider.
What are the most serious risks associated with Lapatinib Teva?+
Serious risks include cardiac dysfunction (reduced left‑ventricular ejection fraction), severe skin reactions such as Stevens‑Johnson syndrome, hepatotoxicity, interstitial lung disease, and significant diarrhea that can lead to dehydration. Patients should be monitored closely for these events.
Who should not use Lapatinib Teva?+
Lapatinib Teva is contraindicated in patients with known hypersensitivity to lapatinib or any of its excipients. Caution is also advised for individuals with pre‑existing cardiac disease, severe liver impairment, or those taking strong CYP3A4 inducers or inhibitors without appropriate monitoring.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lapatinib
Route
Oral Use
Manufacturer
Teva Pharmaceuticals Cr, S.R.O.
Origin
EU

Related products

TYKERB 250 mg/1

TYKERB 250 mg/1

Lapatinib · 250 mg

Tykerb
TABLET
Novartis Pharmaceuticals Corporation
USA
Lapatinib 250 mg/1

Lapatinib 250 mg/1

Lapatinib · 250 mg

Lapatinib
TABLET, FILM COATED
Teva Pharmaceuticals, Inc.
USA
Brastib

Brastib

Lapatinib

Stada Arzneimittel Ag
EU
Brastib

Brastib

Lapatinib

Stada Arzneimittel Ag
EU